Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 19/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4313287 | 0.95 | AGTR2 (0.48) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL1724215 | 0.91 | AGTR2 (0.52) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4327781 | 0.91 | AGTR2 (0.45) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL27973726 | 0.90 | AGTR2 (0.44) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4306715 | 0.90 | AGTR2 (0.43) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL27973576 | 0.87 | AGTR2 (0.42) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL27973544 | 0.85 | AGTR2 (0.62) | AGTR2 | |
| SCHEMBL1724924 | 0.84 | AGTR2 (0.54) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL28813223 | 0.79 | AGTR2 (0.39) | AGTR2CYP2C9CYP2B6AGTR1 | |
| SCHEMBL1719714 | 0.76 | AGTR2 (0.81) | AGTR2CYP2C9CYP2B6AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885CYP2C9 1127/4885CYP2B6 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.